Literature DB >> 3230130

Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis.

A Albus1, J M Fournier, C Wolz, A Boutonnier, M Ranke, N Høiby, H Hochkeppel, G Döring.   

Abstract

Chronic respiratory tract infections caused by Staphylococcus aureus are common in patients with cystic fibrosis (CF). Recently, it was shown in a few CF patients that S. aureus isolates produce capsular polysaccharides (CPs). However, it is not known whether this is a common feature and whether an immune response to CPs in CF is detectable. Therefore, we examined 170 S. aureus isolates from CF patients and healthy individuals for production of CP types 5 and 8 by using monoclonal antibodies. We found that CP-producing staphylococcal isolates were randomly distributed among CF patients and healthy carriers. Eighty-five percent of all isolates produced CPs, 77% of which were type 8. Examination of one sputum sample by an immunofluorescence technique suggested that production of CPs is not an in vitro phenomenon. S. aureus isolates from various sites of a single person often yielded more than one CP type. A random distribution of S. aureus strains with CP type 5 or 8 from the skin and respiratory tracts of patients and from the skin of healthy individuals was found. Antibody response to CP types 5 and 8, measured by enzyme-linked immunosorbent assay, was not elevated in CF patients with chronic S. aureus lung infection in comparison with healthy carriers. On the contrary, in CF patients the ratios of antibodies to CP 8 were significantly lower (P less than 0.005; alpha = 0.025). The ratios of antibodies to CP types did not change when monitored longitudinally over several months. This study suggests that the production of CPs is a universal property of S. aureus and that infected CF patients do not have elevated ratios of antibodies to these antigens.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3230130      PMCID: PMC266934          DOI: 10.1128/jcm.26.12.2505-2509.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  SERUM ANTIBODIES IN STAPHYLOCOCCAL DISEASE.

Authors:  P QUIE; L W WANNAMAKER
Journal:  Pediatrics       Date:  1964-01       Impact factor: 7.124

2.  [Influence of "clumping factor" from Staphylococcus aureus on phagocytosis (author's transl)].

Authors:  K D Hasche; J Brückler; W Schaeg; H Blobel
Journal:  Zentralbl Bakteriol Orig A       Date:  1975-08

Review 3.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

Review 4.  Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumonococci.

Authors:  J J Langone
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

5.  Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections.

Authors:  H A Verbrugh; R Peters; M Rozenberg-Arska; P K Peterson; J Verhoef
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

6.  Immunogenicity of group A and group C meningococcal polysaccharides in human infants.

Authors:  I Goldschneider; M L Lepow; E C Gotschlich; F T Mauck; F Bachl; M Randolph
Journal:  J Infect Dis       Date:  1973-12       Impact factor: 5.226

7.  Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.

Authors:  H A Verbrugh; P K Peterson; B Y Nguyen; S P Sisson; Y Kim
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

8.  The role of antibodies against alpha-toxin and teichoic acid in the diagnosis of staphylococcal infections.

Authors:  I G Julander; M Granström; S A Hedström; R Möllby
Journal:  Infection       Date:  1983 Mar-Apr       Impact factor: 3.553

9.  Binding of fibronectin to Staphylococcus strains.

Authors:  L M Switalski; C Rydén; K Rubin; A Ljungh; M Höök; T Wadström
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

10.  Phagocytosis, bacterial killing, and metabolism by purified human lung phagocytes.

Authors:  J R Hoidal; D Schmeling; P K Peterson
Journal:  J Infect Dis       Date:  1981-07       Impact factor: 5.226

View more
  23 in total

1.  Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus.

Authors:  S Ouyang; S Sau; C Y Lee
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

2.  Respiratory activity is essential for post-exponential-phase production of type 5 capsular polysaccharide by Staphylococcus aureus.

Authors:  B Dassy; J M Fournier
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Regulation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides by CO(2).

Authors:  S Herbert; S W Newell; C Lee; K P Wieland; B Dassy; J M Fournier; C Wolz; G Döring
Journal:  J Bacteriol       Date:  2001-08       Impact factor: 3.490

Review 4.  Cystic fibrosis. Infection and immunity to Staphylococcus aureus and Haemophilus influenzae.

Authors:  D P Greenberg; H R Stutman
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

Review 5.  Clinical significance of Staphylococcus aureus in cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1990 Jan-Feb       Impact factor: 3.553

6.  Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus.

Authors:  W S Lin; T Cunneen; C Y Lee
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

7.  Virulence of Staphylococcus aureus mutants altered in type 5 capsule production.

Authors:  A Albus; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

8.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  S Xu; R D Arbeit; J C Lee
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

Review 9.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus.

Authors:  J C Lee; S Takeda; P J Livolsi; L C Paoletti
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.